Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
South Med J ; 107(2): 107-13, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24926677

RESUMO

Nitrofurantoin is a commonly prescribed antibiotic for the treatment of recurrent uncomplicated urinary tract infections. Its importance has been emphasized by the current international clinical practice guidelines for the management of uncomplicated cystitis. Since its introduction into clinical practice, nitrofurantoin has been associated with various adverse effects, including hepatotoxicity. We searched the English-language literature using PubMed and SCOPUS for the period 1961 through the end of February 2013. Key search terms included "nitrofurantoin AND hepatotoxicity" as well as "nitrofurantoin AND hepatitis." When studies or case reports were found, we assessed articles cited in those publications. A broad spectrum of liver toxicity associated with nitrofurantoin use has been reported, ranging from acute hepatitis, granulomatous reaction, cholestasis, or autoimmune-mediated hepatitis to chronic active hepatitis that could lead to cirrhosis or death. The mechanism of hepatotoxicity is poorly understood, but it is believed to be the result of an immunologic process or a direct cytotoxic reaction. It has been postulated that prolonged exposure to nitrofurantoin, female sex, advanced age, and reduced renal function increase the risk of developing hepatotoxicity. For the management of severe cases, corticosteroids have been used along with nitrofurantoin discontinuation. Because of mixed results, the utility of corticosteroids has not been proven and should be used judiciously. Given the severity and seriousness of the adverse effect of hepatotoxicity, clinicians should weigh the risks and benefits of nitrofurantoin before initiating therapy, especially in long-term prophylaxis in high-risk patients. Clinicians also should be well versed in recognizing and managing liver injury associated with nitrofurantoin.


Assuntos
Anti-Infecciosos Urinários/efeitos adversos , Doença Hepática Induzida por Substâncias e Drogas , Fígado/efeitos dos fármacos , Nitrofurantoína/efeitos adversos , Infecções Urinárias/tratamento farmacológico , Doença Aguda , Anti-Infecciosos Urinários/uso terapêutico , Humanos , Nitrofurantoína/uso terapêutico , Medição de Risco
2.
J Asthma ; 47(10): 1123-7, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21039210

RESUMO

BACKGROUND: Oral corticosteroids (OCS) in the home management of asthma exacerbations have been recommended in the NIH/NHLBI guidelines since 1991. As a routine component of written action plans, OCS treatment at home is associated with reduced emergency department (ED) visits and hospitalizations as well as decreased mortality. METHODS: A literature search of English language journals from 1991 to 2009 was performed using several databases, including PubMed, EMBASE, and SCOPUS. We assessed studies that evaluated adherence to national guidelines for home management of asthma exacerbations. RESULTS: Our review of the literature found that several studies reveal that a small percentage (<3-26%) of patients are receiving OCS at home to manage asthma exacerbations prior to an ED visit. Additional studies were found showing very low use of written action plans, strongly suggesting lack of OCS for home management of asthma exacerbations. CONCLUSIONS: Despite evidence of reduced ED visits and hospitalizations and the recommendations of national and international guidelines, the home use of OCS in managing asthma exacerbations remains unacceptably low. New strategies are needed to ensure home use of OCS as part of written action plans to prevent ED visits and hospitalizations for asthma exacerbations.


Assuntos
Corticosteroides/administração & dosagem , Antiasmáticos/administração & dosagem , Asma/tratamento farmacológico , Serviço Hospitalar de Emergência/normas , Fidelidade a Diretrizes , Criança , Hospitalização , Humanos , National Institutes of Health (U.S.) , Estados Unidos
3.
J Pharm Pract ; 32(2): 225-227, 2019 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-29241388

RESUMO

BACKGROUND: Calcium carbonate is often used to relieve Gastroesophageal Reflux Disease (GERD) in pregnant patients. This report describes a potentially serious complication. CASE: A pregnant female presented at 34 weeks gestation with abdominal pain, nausea, and vomiting. Home medications included an unquantifiable amount of calcium carbonate 500 mg due to constant consumption for GERD. Laboratory findings included elevated calcium, amylase, lipase, and triglyceride level. Pancreatitis was diagnosed and abdominal ultrasound excluded gallstones. Despite hydration, lipase rose and emergency cesarean section was performed. Hypercalcemia was managed by intravenous fluid administration. After delivery, pancreatitis resolved. CONCLUSION: Pancreatitis developed in pregnant patient with hypercalcemia due to excessive calcium carbonate ingestion and resolved after delivery of the fetus, fluid resuscitation, and return of calcium level to normal.


Assuntos
Carbonato de Cálcio/efeitos adversos , Hipercalcemia/induzido quimicamente , Pancreatite/sangue , Pancreatite/induzido quimicamente , Complicações na Gravidez/sangue , Complicações na Gravidez/induzido quimicamente , Adulto , Cesárea , Feminino , Refluxo Gastroesofágico/tratamento farmacológico , Humanos , Gravidez
4.
In Vivo ; 31(1): 121-124, 2017 01 02.
Artigo em Inglês | MEDLINE | ID: mdl-28064230

RESUMO

BACKGROUND: Thiamine deficiency can lead to Wernicke's encephalopathy (WE), an acute and potentially life-threatening neurological disorder. Even though the main treatment modality for WE consists of thiamine replacement, evidence supporting an optimal dosing strategy and duration is unclear. PATIENTS AND METHODS: We present a single-center case series of eleven patients that were admitted with possible WE and treated with high-dose parenteral thiamine. RESULTS: Patients with suspected WE were treated with ≥500 mg intravenous thiamine for a median of 3 days with 73% of patients (eight out of eleven) displaying symptom resolution or improvement after treatment. No significant correlation between symptom resolution and timing of high-dose thiamine initiation (median=92 h) was identified. In patients whose symptoms resolved compared to those whose symptoms did not, there were no differences in patient variables nor adverse effects related to thiamine treatment. CONCLUSION: High-dose thiamine (≥500 mg) appears safe and efficacious for use in patients with suspected WE.


Assuntos
Deficiência de Tiamina/complicações , Tiamina/uso terapêutico , Complexo Vitamínico B/uso terapêutico , Encefalopatia de Wernicke/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Relação Dose-Resposta a Droga , Feminino , Humanos , Pessoa de Meia-Idade , Prognóstico , Encefalopatia de Wernicke/etiologia
5.
Am J Med Sci ; 345(2): 160-2, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23103438

RESUMO

Corrected QT-interval (QTc) prolongation with increased risk of fatal arrhythmia is a well-established toxicity of methadone. In this study, a case of sudden cardiac arrest in a patient on chronic methadone therapy is presented. A 47-year-old man presented unresponsive to the emergency department after pulseless arrest at his home. The patient's wife revealed he was taking methadone as part of an ongoing opioid dependency treatment and that he was prescribed azithromycin for an upper respiratory tract infection 3 days before his presentation. A 12-lead electrocardiogram at the time of presentation showed sinus tachycardia and a QTc of 490 milliseconds. It was concluded that the patient experienced a fatal arrhythmia because of QTc prolongation, precipitated by azithromycin in the setting of ongoing methadone use.


Assuntos
Azitromicina/efeitos adversos , Morte Súbita Cardíaca/etiologia , Metadona/efeitos adversos , Azitromicina/administração & dosagem , Quimioterapia Combinada , Parada Cardíaca/induzido quimicamente , Parada Cardíaca/diagnóstico , Humanos , Masculino , Metadona/administração & dosagem , Pessoa de Meia-Idade
6.
Respir Care ; 58(3): 494-7, 2013 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22906434

RESUMO

BACKGROUND: Current guidelines for the correct peak expiratory flow (PEF) maneuver include standing. In the hospital setting, PEF values are often ordered to assess response to asthma therapy for exacerbations. We have observed that the PEF is sometimes performed with the patient in bed. METHODS: Healthy adults performed the PEF maneuver in random order, standing, lying back at an ~45° angle on pillows, and sitting, slumped forward ~10° with legs extended. PEF was recorded for 3 attempts in each of the 3 positions. RESULTS: We enrolled 94 subjects (39 male, 55 female, mean age 24 y) in 2011. Mean PEF in the standing position (669 ± 42 L/min) was significantly higher than in the lying back (621 ± 42 L/min) (P < .001) and sitting (615 ± 42 L/min) positions in males (P < .001), and, similarly, in females, standing produced a significantly higher mean PEF (462 ± 42 L/min) than the lying back (422 ± 42 L/min) (P < .001) and sitting (447 ± 42 L/min) positions (P < .05). CONCLUSIONS: Clinicians should ensure that PEF is obtained with patients out of bed and in the standing position.


Assuntos
Leitos , Pico do Fluxo Expiratório/fisiologia , Postura/fisiologia , Adulto , Asma/fisiopatologia , Feminino , Humanos , Masculino , Estudos Prospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA